NCT04691622 - Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 17, 2022

Primary Completion Date

August 30, 2028

Study Completion Date

October 30, 2028

Conditions

Viral InfectionHematopoietic Stem Cell Transplantation (HSCT)Primary Immunodeficiency Disorders (PID)

Interventions

BIOLOGICAL

Norovirus -specific T-cell (NST) therapy

"Arm A: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion.~Arm B: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion."

Trial Locations (3)

20010

RECRUITING

Children's National Hospital, Washington D.C.

20892

RECRUITING

National Institutes of Health (NIH), Bethesda

21287

RECRUITING

Johns Hopkins University, Baltimore